Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Current Investments (2021 - 2026)

Krystal Biotech (KRYS) has disclosed Cash & Current Investments for 5 consecutive years, with $827.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 38.54% to $827.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $827.8 million through Dec 2025, up 38.54% year-over-year, with the annual reading at $827.8 million for FY2025, 38.54% up from the prior year.
  • Cash & Current Investments hit $827.8 million in Q4 2025 for Krystal Biotech, up from $731.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $827.8 million in Q4 2025 to a low of $343.1 million in Q3 2021.
  • Historically, Cash & Current Investments has averaged $512.5 million across 5 years, with a median of $504.8 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: fell 19.38% in 2023 and later surged 53.62% in 2024.
  • Year by year, Cash & Current Investments stood at $438.1 million in 2021, then decreased by 13.45% to $379.2 million in 2022, then soared by 40.35% to $532.2 million in 2023, then grew by 12.28% to $597.5 million in 2024, then skyrocketed by 38.54% to $827.8 million in 2025.
  • Business Quant data shows Cash & Current Investments for KRYS at $827.8 million in Q4 2025, $731.1 million in Q3 2025, and $682.0 million in Q2 2025.